An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study to Compare Two Strengths (10 mg and 20 mg) of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Senaparib (Primary)
- Indications Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors IMPACT Therapeutics
Most Recent Events
- 27 May 2022 New trial record